Hanmi's New Story
Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi
Meet Us at BIO-IT World 2025.
Identification and Validation of Predictive Biomarker of EZH1/2 Dual Inhibitor, HM97662, through Bioinformatics Analysis
- Poster Number
- P28
- Session
- Reception & Break, Apr 2 at 18:10 PM ~ Apr 4 at 14:30 PM
- Presenter
- Seungheon Baek / Hanmi Pharmaceutical
Meet Us at AACR 2025.
Advancing immunotherapy with the development of a novel STING mRNA analog
- Poster Number
- LB038
- Session
- Poster Section 51, Apr 27 at 14:00~17:00 PM
- Presenter
-
Yong Ho Heo, Ph.D. /
Hanmi Pharmaceutical
Strong synergistic activity of an EZH1/2 dual inhibitor, HM97662, in combination with standard chemotherapy in preclinical models of advanced solid tumors
- Poster Number
- 1681
- Session
- Poster Section 19, Apr 28 at 9:00 AM~12:00 PM
- Presenter
-
Seung Hyun Jung, Ph.D. /
Hanmi Pharmaceutical
Preclinical efficacy of a selective, orally bioavailable HER2 small molecule inhibitor targeting HER2 alterations and Enhertu-resistant cancers
- Poster Number
- 1744
- Session
- Poster Section 44, Apr 28 at 9:00 AM~12:00 PM
- Presenter
-
Jiyoung Jeon, Ph.D. /
Hanmi Pharmaceutical
HM100760, a potent and selective MAT2A inhibitor, demonstrates a synergistic anticancer effect when combined with a PRMT5 inhibitor in MTAP-deleted cancer
- Poster Number
- 1770
- Session
- Poster Section 22, Apr 28 at 9:00 AM~12:00 PM
- Presenter
-
Minjeong Kim /
Hanmi Pharmaceutical
NGS-based molecular profiling reveals remarkable anticancer synergy of EZH1/2 dual inhibitor HM97662 with standard-of-care therapy on small cell lung cancer
- Poster Number
- 2405
- Session
- Poster Section 44, Apr 28 at 9:00 AM~12:00 PM
- Presenter
-
Jooyun Byun, Ph.D. /
Hanmi Pharmaceutical
Development of Selective HER2 Covalent Inhibitors with Brain Penetration for Effective Treatment of CNS Metastases
- Poster Number
- 2935
- Session
- Poster Section 21, Apr 28 at 14:00~17:00 PM
- Presenter
-
Yu-Yon Kim, Ph.D. /
Hanmi Pharmaceutical
Transcriptional modulations of tumor microenvironment by BH3120, a PD-L1x4-1BB bispecific antibody, in patient-derived organotypic tumor spheroids (PDOTS) model
- Poster Number
- 3411
- Session
- Poster Section 35, Apr 28 at 14:00~17:00 PM
- Presenter
-
Jun Wang /
Beijing Hanmi Pharmaceutical
Employing synthetic mRNA therapeutic platform to restore p53 function to suppress growth of p53 mutant cancer
- Poster Number
- 4330
- Session
- Poster Section 19, Apr 29 at 9:00 AM~12:00 PM
- Presenter
-
Innah Kim /
Hanmi Pharmaceutical
BH3120, a PD-L1x4-1BB bispecific antibody, exhibits favorable safety profiles in distinct in vivo and ex vivo liver toxicity evaluations
- Poster Number
- 4345
- Session
- Poster Section 20, Apr 29 at 9:00 AM~12:00 PM
- Presenter
-
Jing Wang /
Beijing Hanmi Pharmaceutical
Hanmi’s p53 mRNA and abraxane synergistically promote tumor control in PTX-prefered cancer through p53 stabilization
- Poster Number
- 5696
- Session
- Poster Section 23, Apr 29 at 14:00~17:00 PM
- Presenter
-
Heesun Moon /
Hanmi Pharmaceutical
Discovery of a novel SOS1-KRASmulti inhibitor, HM101207, demonstrates a broad-spectrum antitumor activity across KRAS-MAPK mutant cancers
- Poster Number
- LB429
- Session
- Poster Section 51, Apr 30 at 9:00 AM~12:00 PM
- Presenter
-
Jaeyul Choi /
Hanmi Pharmaceutical
